Presentation is loading. Please wait.

Presentation is loading. Please wait.

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 5 Pharmacodynamics.

Similar presentations


Presentation on theme: "Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 5 Pharmacodynamics."— Presentation transcript:

1 Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 5 Pharmacodynamics

2 2Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Pharmacodynamics  The study of the biochemical and physiologic effects of drugs and the molecular mechanisms by which those effects are produced  The study of what drugs do to the body and how they do it

3 3Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Therapeutic Objective  To accomplish the therapeutic objective, nurses must have a basic understanding of pharmacodynamics  Educating patients about their medications  Making PRN decisions  Evaluating patients for drug responses (both beneficial and harmful)  Collaborating with physicians about drug therapy

4 4Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Pharmacodynamics  Dose-response relationships  Drug-receptor interactions  Drug responses that do not involve receptors  Interpatient variability in drug responses  The therapeutic index

5 5Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Dose-Response Relationships  Relationship between the size of an administered dose and the intensity of the response produced  Determines  The minimum amount of drug we can use  The maximum response a drug can elicit  How much we need to increase the dosage to produce the desired increase in response

6 6Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Dose-Response Relationships  As the dosage increases, the response becomes progressively larger.  Tailor treatment by increased/decreased dosage until desired intensity of response is achieved.  Three phases occur (see Figure 5-1).

7 7Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Fig Basic components of the dose-response curve. A, A dose-response curve with dose plotted on a linear scale. B, The same dose-response relationship shown in A but with the dose plotted on a logarithmic scale. Note the three phases of the dose-response curve: Phase 1, The curve is relatively flat; doses are too low to elicit a significant response. Phase 2, The curve climbs upward as bigger doses elicit a corresponding increase in response. Phase 3, The curve levels off; bigger doses are unable to elicit a further increase in response. (Phase 1 is not indicated in A because very low doses cannot be shown on a linear scale.)

8 8Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Maximal Efficacy and Relative Potency   These two characteristic properties of drugs are revealed in dose-response curves.   Maximal efficacy   The largest effect that a drug can produce (height of the curve; see Fig. 5-2A)   Match the intensity of the response with the patient’s need.   Very high maximal efficacy is not always more desirable. Don’t hunt squirrels with a cannon.

9 9Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Fig Dose-response curves demonstrating efficacy and potency. A, Efficacy, or “maximal efficacy,” is an index of the maximal response a drug can produce. The efficacy of a drug is indicated by the height of its dose-response curve. In this example, meperidine has greater efficacy than pentazocine. Efficacy is an important quality in a drug. B, Potency is an index of how much drug must be administered to elicit a desired response. In this example, achieving pain relief with meperidine requires higher doses than with morphine. We would say that morphine is more potent than meperidine. Note that, if administered in sufficiently high doses, meperidine can produce just as much pain relief as morphine. Potency is usually not an important quality in a drug.

10 10Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Maximal Efficacy and Relative Potency   Relative potency   The amount of drug we must give to elicit an effect (see Fig. 5-2B)   Rarely an important characteristic of the drug   Can be important if lack of potency forces inconveniently large doses   Implies nothing about maximal efficacy – refers to dosage needed to produce effects

11 11Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Drug-Receptor Interactions  Drugs  Chemicals that produce effects by interacting with other chemicals  Receptors  Special chemicals in the body that most drugs interact with to produce effects

12 12Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Receptor  A receptor is any functional macromolecule in a cell to which a drug binds to produce its effects.  Technically, receptors can include enzymes, ribosomes, tubulin, etc.  The term receptor is generally reserved for the body’s own receptors for  Hormones, neurotransmitters, and other regulatory molecules

13 13Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Receptor Binding  Binding of a drug to its receptor is usually reversible.  Receptor activity is regulated by endogenous compounds.  When a drug binds to a receptor, it will mimic or block the action of the endogenous regulatory molecules and increase or decrease the rate of physiologic activity normally controlled by that receptor.

14 14Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Fig Interaction of drugs with receptors for norepinephrine. Under physiologic conditions, cardiac output can be increased by the binding of norepinephrine (NE) to receptors (R) on the heart. Norepinephrine is supplied to these receptors by nerves. These same receptors can be acted on by drugs, which can mimic the actions of endogenous NE (and thereby increase cardiac output) or block the actions of endogenous NE (and thereby reduce cardiac output).

15 15Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Important Properties of Receptors  Receptors are normal points of control of physiologic processes.  Under physiologic conditions, receptor function is regulated by molecules supplied by the body.  Drugs can only mimic or block the body’s own regulatory molecules.  Drugs cannot give cells new functions.

16 16Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Important Properties of Receptors  Drugs produce their therapeutic effects by helping the body use its preexisting capabilities.  In theory, it should be possible to synthesize drugs that can alter the rate of any biologic process for which receptors exist.

17 17Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Four Primary Receptor Families  Cell membrane–embedded enzymes  Ligand-gated ion channels  G protein–coupled receptor systems  Transcription factors

18 18Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Fig The four primary receptor families. 1, Cell membrane–embedded enzyme. 2, Ligand-gated ion channel. 3, G protein–coupled receptor system (G = G protein). 4, Transcription factor. (See text for details.)

19 19Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Receptors and Selectivity of Drug Action  The more selective a drug is, the fewer side effects it will produce.  Receptors make selectivity possible.  Each type of receptor participates in the regulation of just a few processes.

20 20Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Receptors and Selectivity of Drug Action  Lock and key mechanism  Does not guarantee safety  Body has receptors for each:  Neurotransmitter  Hormone  All other molecules in the body used to regulate physiologic processes

21 21Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Fig Interaction of acetylcholine with its receptor. A, Three-dimensional model of the acetylcholine molecule. B, Binding of acetylcholine to its receptor. Note how the shape of acetylcholine closely matches the shape of the receptor. Note also how the positive charges on acetylcholine align with the negative sites on the receptor.

22 22Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Theories of Drug-Receptor Interaction  Simple occupancy theory  Modified occupancy theory  Affinity Strength of the attraction Strength of the attraction  Intrinsic activity Ability of the drug to activate a receptor upon binding Ability of the drug to activate a receptor upon binding

23 23Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Fig Model of simple occupancy theory. The simple occupancy theory states that the intensity of response to a drug is proportional to the number of receptors occupied; maximal response is reached with 100% receptor occupancy. Because the hypothetical cell in this figure has only four receptors, maximal response is achieved when all four receptors are occupied. (Please note: Real cells have thousands of receptors.)

24 24Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Drug-Receptor Interactions  Agonists, antagonists, and partial agonists  Agonists  Antagonists  Noncompetitive vs. competitive antagonists  Partial agonists

25 25Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Agonists  Agonists are molecules that activate receptors.  Endogenous regulators are considered agonists.  Agonists have both affinity and high intrinsic activity.  Dobutamine mimics norepinephrine at cardiac receptors.  Agonists can make processes go “faster” or “slower.”

26 26Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Antagonists  Produce their effects by preventing receptor activation by endogenous regulatory molecules and drugs  Affinity but no intrinsic activity  No effects of their own on receptor function

27 27Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Antagonists  Do not cause receptor activation but cause pharmacologic effects by preventing the activation of receptors by agonists  If there is no agonist present, an antagonist will have no observable effect.

28 28Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Noncompetitive vs. Competitive Antagonists  Noncompetitive antagonists  Bind irreversibly to receptors  Reduce the maximal response that an agonist can elicit (fewer available receptors)  Impact not permanent (cells are constantly breaking down “old” receptors and synthesizing new ones)

29 29Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Noncompetitive vs. Competitive Antagonists  Competitive antagonists  Compete with agonists for receptor binding  Bind reversibly to receptors  Equal affinity: receptor occupied by whichever agent is present in the highest concentration

30 30Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Fig Dose-response curves in the presence of competitive and noncompetitive antagonists. A, Effect of a noncompetitive antagonist on the dose-response curve of an agonist. Note that noncompetitive antagonists decrease the maximal response achievable with an agonist. B, Effect of a competitive antagonist on the dose-response curve of an agonist. Note that the maximal response achievable with the agonist is not reduced. Competitive antagonists simply increase the amount of agonist required to produce any given intensity of response.

31 31Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Partial Agonists  These are agonists that have only moderate intrinsic activity.  The maximal effect that a partial agonist can produce is less than that of a full agonist.  Can act as antagonists as well as agonists

32 32Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Regulation of Receptor Sensitivity  Receptors are dynamic cell components.  Number of receptors on cell surface and sensitivity to agonists can change in response to  Continuous activation  Continuous inhibition

33 33Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Regulation of Receptor Sensitivity  Continuous exposure to agonist  Desensitized or refractory Down-regulation Down-regulation  Continuous exposure to an antagonist  Hypersensitive

34 34Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Drug Responses That Do Not Involve Receptors  Simple physical or chemical interactions with other small molecules  Examples of receptorless drugs  Antacids, antiseptics, saline laxatives, chelating agents

35 35Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Interpatient Variability in Drug Responses  The dose required to produce a therapeutic response can vary substantially among patients.  Measurement of interpatient variability (see Fig. 5-8)  The ED 50

36 36Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Fig Interpatient variation in drug responses. A, Data from tests of a hypothetical acid suppressant in 100 patients. The goal of the study is to determine the dosage required by each patient to elevate gastric pH to 5. Note the wide variability in doses needed to produce the target response for the 100 subjects. B, Frequency distribution curve for the data in A. The dose at the middle of the curve is termed the ED 50 —the dose that will produce a predefined intensity of response in 50% of the population.

37 37Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Interpatient Variability in Drug Responses  Clinical implications of interpatient variability  The initial dose of a drug is necessarily an approximation.  Subsequent doses must be “fine tuned” based on the patient’s response.  ED 50 in a patient may need to be increased or decreased after the patient response is evaluated.

38 38Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Therapeutic Index  Measure of a drug’s safety  Ratio of the drug’s LD 50 (average lethal dose to 50% of the animals treated) to its ED 50  The larger/higher the therapeutic index, the safer the drug.  The smaller/lower the therapeutic index, the less safe the drug.

39 39Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Fig The therapeutic index. A, Frequency distribution curves indicating the ED50 and LD50 for drug “X.” Because its LD 50 is much greater than its ED 50, drug X is relatively safe. B, Frequency distribution curves indicating the ED 50 and LD 50 for drug “Y.” Because its LD 50 is very close to its ED 50, drug “Y” is not very safe. Also note the overlap between the effective-dose curve and the lethal-dose curve.


Download ppt "Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 5 Pharmacodynamics."

Similar presentations


Ads by Google